Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 13Other hematologic neoplasm 9Lymphoid 6Thoracic 4Sarcoma 3Tumor-Agnostic 1Plasma cell 1Myeloid 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Recurrence 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 259fludarabine phosphate 232Azacitidine 180fludarabine 179Busulfan 174Cytarabine 154Mycophenolic Acid 147Tacrolimus 145Whole-Body Irradiation 141Imatinib Mesylate 141Peripheral Blood Stem Cell Transplantation 139Cyclosporine 110Antilymphocyte Serum 108Melphalan 106Methotrexate 105Filgrastim 101Decitabine 98nilotinib 82venetoclax 77ruxolitinib 72Granulocyte Colony-Stimulating Factor 66Stem Cell Transplantation 62Dasatinib 62Thiotepa 60Radiotherapy 60thymoglobulin 52Specimen Handling 49Etoposide 49Clofarabine 46Cord Blood Stem Cell Transplantation 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × devimistat × Myeloid × Clear all
NCT01520805 2016-12-29

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

Cornerstone Pharmaceuticals

Phase 2 Withdrawn
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡